CAG
DFTX

Crestwood Advisors Group’s Definium Therapeutics DFTX Stock Holding History

Crestwood Advisors Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,467
Closed -$14K – 275
2022
Q2 		$14K Buy
+1,467
New +$18.6K ﹤0.01% 267

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Crestwood Advisors Group's DFTX Position: Q3 2022 in Review

Crestwood Advisors Group sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,467 shares — an estimated $14K sold.

Crestwood Advisors Group first reported a position in DFTX in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Crestwood Advisors Group reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Crestwood Advisors Group sold 1,467 Definium Therapeutics shares in Q3 2022, an estimated $14K.
  • Crestwood Advisors Group first reported a position in Definium Therapeutics in Q2 2022 and held it in 1 quarter.
  • Crestwood Advisors Group's Definium Therapeutics position peaked at $14K in Q2 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Crestwood Advisors Group's 13F filing for Q3 2022, filed 26 Oct 2022.